A phase II study of erlotinib in combination with bevacizumab versus chemotherapy plus bevacizumab in the first-line treatment of advanced non-squamous non-small cell lung cancer

Lung Cancer

Volumn 82, Issue 2, 2013, Pages 276-281

  Ciuleanu, T ^a,b   Tsai, C M ^c   Tsao, C J ^d   Milanowski, J ^e   Amoroso, D ^f   Heo, D S ^g   Groen, H J M ^h   Szczesna, A ⁱ   Chung, C Y ^j   Chao, T Y ^k   Middleton, G ^l   Zeaiter, A ^m   Klingelschmitt, G ^m   Klughammer, B ^m   Thatcher, N ⁿ  

^a THE ONCOLOGY INSTITUTE PROF DR ION CHIRICUTA   (Romania)

^b IULIU HATIEGANU UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^c TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^d Chi Mei Medical Centre   (Taiwan)

^e MEDICAL UNIVERSITY OF LUBLIN   (Poland)

^f ISTITUTO TOSCANO TUMORI   (Italy)

^g Seoul National University College of Medicine   (South Korea)

^h UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

ⁱ Division III   (Poland)

^j CHANGHUA CHRISTIAN HOSPITAL   (Taiwan)

^k TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^l ROYAL SURREY COUNTY HOSPITAL   (United Kingdom)

^m F HOFFMANN LA ROCHE LTD   (Switzerland)

ⁿ CHRISTIE HOSPITAL   (United Kingdom)

more..

Author keywords

Bevacizumab; Combination therapy; Erlotinib; First line; Non small cell lung cancer; Non squamous

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CISPLATIN; ERLOTINIB; GEMCITABINE; PACLITAXEL;

ADULT; ADVANCED CANCER; ADVERSE OUTCOME; AGED; ALGORITHM; ALOPECIA; ANEMIA; ARTICLE; ASTHENIA; BACKACHE; BRONCHITIS; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER SURVIVAL; COMPARATIVE STUDY; CONSTIPATION; CONTROLLED STUDY; COUGHING; DIARRHEA; DISEASE COURSE; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRY SKIN; DYSPEPSIA; DYSPHONIA; DYSPNEA; EPISTAXIS; FATIGUE; FEMALE; HAZARD RATIO; HEADACHE; HEMOPTYSIS; HUMAN; HYPERTENSION; INSOMNIA; LEUKOPENIA; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; MUSCULOSKELETAL DISEASE; MYALGIA; NAUSEA; NEUROPATHY; NEUTROPENIA; OROPHARYNX PAIN; OVERALL SURVIVAL; PARONYCHIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEINURIA; PRURITUS; RANDOMIZED CONTROLLED TRIAL; STOMATITIS; THROMBOCYTOPENIA; TREATMENT OUTCOME; UPPER ABDOMINAL PAIN; UPPER RESPIRATORY TRACT INFECTION; VOMITING;

BEVACIZUMAB; COMBINATION THERAPY; ERLOTINIB; FIRST-LINE; NON-SMALL CELL LUNG CANCER; NON-SQUAMOUS;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; QUINAZOLINES; RISK FACTORS; TREATMENT OUTCOME;

EID: 84887018257     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2013.08.002     Document Type: Article

References (30)

1. Jemal A., Bray F., Center M., Ferlay J., Ward E., Forman D. Global cancer statistics. CA Cancer J Clin 2011, 61:69-90.
2. Siegel R., Naishadham D., Jemal A. Cancer statistics 2012. CA Cancer J Clin 2012, 62:10-29.
3. Schiller J., Harrington D., Belani C., Langer C., Sandler A., Krook J., et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002, 346:92-98.
4. Socinski M., Evans T., Gettinger S., Hensing T., Sequist L., Ireland B., et al. Treatment of stage IV non-small cell lung cancer: diagnosis and management of lung cancer, 3rd ed.: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2013, 143:341-368.
5. Jain H., Jackson T. A hybrid model of the role of VEGF binding in endothelial cell migration and capillary formation. Front Oncol 2013, 3:102.
6. Sandler A., Gray R., Perry M., Brahmer J., Schiller J., Dowlati A., et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006, 355:2542-2550.
7. Reck M., von Pawel J., Zatloukal P., Ramlau R., Gorbounova V., Hirsh V., et al. Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomized phase III trial (AVAiL). Ann Oncol 2010, 21:1804-1809.
8. Crino L., Dansin E., Garrido P., Griesinger F., Laskin J., Pavlakis N., et al. Safety and efficacy of first-line bevacizumab-based therapy in advanced non-squamous non-small-cell lung cancer (SAiL, MO19390): a phase 4 study. Lancet Oncol 2010, 11:733-740.
9. Ripamonti F., Albano L., Rossini A., Borrelli A., Fabris S., Mantouani R., et al. EGFR through STAT3 modulates N63α expression to sustain tumor-initiating cell proliferation in squamous cell carcinomas. J Cell Physiol 2013, 228:871-878.
10. Shepherd F.A., Rodrigues Pereira J., Ciuleanu T., Tan E., Hirsch V., Thongprasert S., et al. Erlotinib in previously treated non-small cell lung cancer. N Engl J Med 2005, 353:123-132.
11. Bezjak A., Tu D., Seymour L., Clark G., Trajkovic A., Zukin A., et al. Symptom improvement in lung cancer patients treated with erlotinib: quality of life analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21. J Clin Oncol 2006, 24:3831-3837.
12. Reck M., van Zandwijk N., Gridelli C., Baliko Z., Rischin D., Allan S., et al. Erlotinib in advanced non-small cell lung cancer: efficacy and safety findings of the global phase IV Tarceva lung cancer survival study. J Thorac Oncol 2010, 5:1616-1622.
13. Zhou C., Wu Y., Chen G., Feng J., Lui X., Wang C., et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 2011, 12:735-742.
14. Rosell R., Carcereny E., Gervais R., Vergnenegre A., Massuti B., Felip E., et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2012, 13:239-246.
15. Cappuzzo F., Ciuleanu T., Stelmakh L., Cicena S., Szczesna A., Juhasz E., et al. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol 2010, 11:521-529.
16. Lilenbaum R., Axelrod R., Thomas S., Dowlati A., Seigel L., Albert D., et al. Randomized phase II trial of erlotinib or standard chemotherapy in patients with advanced non-small-cell lung cancer and a performance status of 2. J Clin Oncol 2008, 26:863-869.
17. Gridelli C., Ciardiello F., Gallo C., Feld R., Butts C., Gebbia V., et al. First-line erlotinib followed by second-line cisplatin-gemcitabine chemotherapy in advanced non-small-cell lung cancer: the TORCH randomized trial. J Clin Oncol 2012, 30:3002-3011.
18. Mok T.S., Wu Y.-L., Thongprasert S., Yang C., Chu D., Saijo N., et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009, 361:947-957.
19. Han J-Y., Park K., Kim S-W., Lee D., Kim H.Y., Kim H.T., et al. First-SIGNAL: first-line single agent Iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung. J Clin Oncol 2012, 30:1122-1128.
20. Herbst R.S., Johnson D., Mininberg E., Carbone D., Henderson T., Kim E., et al. Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer. J Clin Oncol 2005, 23:2544-2555.
21. Herbst R.S., O'Neill V., Fehrenbacher L., Belani C., Bonomi P., Hart L., et al. Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer. J Clin Oncol 2007, 25:4743-4750.
22. Sandler A., Herbst R. Combining targeted agents: blocking the epidermal growth factor and vascular endothelial growth factor pathways. Clin Cancer Res 2006, 12:4421-4425.
23. Besse B., Le Moulec S., Senellart H., Mazieres J., Barlesi F., Dansin E., et al. Phase II study of bevacizumab in combination with first-line chemotherapy or second-line erlotinib in non-squamous NSCLC patients with asymptomatic untreated brain metastases. Ann Oncol 2012, 23(Suppl. 9):426. [Abstract 1299P].
24. Zappa F., Droege C., Betticher D., von Moos R., Bubendorf L., Ochsenbein A., et al. Bevacizumab and erlotinib (BE) first-line therapy in advanced non-squamous non-small-cell lung cancer (NSCLC) (stage IIIB/IV) followed by platinum-based chemotherapy (CT) at disease progression: a multicenter phase II trial (SAKK 19/05). Lung Cancer 2012, 78:239-244.
25. Dingemans A.M., de Langen A.J., van den Boogart V., Marcus J., Backes W., Scholten H., et al. First-line erlotinib and bevacizumab in patients with locally advanced and/or metastatic non-small-cell lung cancer: a phase II study including molecular imaging. Ann Oncol 2010, 22:559-566.
26. Schoenfeld D. Sample-size formula for the proportional-hazards regression model. Biometrics 1983, 39:499-503.
27. Pocock S., Simon R. Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. Biometrics 1975, 31:103-115.
28. Thomas M. Innovations randomized phase II trial of erlotinib (E)/bevacizumab (B) compared with cisplatin (P)/gemcitabine (G) plus B in first-line treatment of advanced nonsquamous (NS) non-small cell lung cancer (NSCLC). J Clin Oncol 2011, 29(Suppl. 15 Pt 1):477. [Abstract 7504].
29. D'Addario G., Rauch D., Stupp R., Pless M., Stahel R., Mach N., et al. Multicentre phase II trial of gefitinib first-line therapy followed by chemotherapy in advanced non-small-cell lung cancer (NSCLC): SAKK protocol 19/03. Ann Oncol 2008, 19:739-745.
30. Raben D., Bunn P.A. Biologically targeted therapies plus chemotherapy plus radiotherapy in stage III non-small-cell lung cancer: a case of the Icarus syndrome?. J Clin Oncol 2012, 30:3909-3912.